Ikena Oncology

Nodus Oncology

This biotechnology company develops small molecule therapeutics targeting DNA damage response pathways to treat patients with molecularly defined cancers.

Bicara Therapeutics

This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.

Black Diamond Therapeutics

This clinical-stage company develops precision oncology medicines and small molecule therapies for patients with genetically defined cancers.

Kinnate Biopharma

The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.

Scorpion Therapeutics

This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.

Ribon Therapeutics

This biotechnology company develops small molecule inhibitors targeting stress support pathways for patients with cancer and inflammatory diseases.

Khora

This clinical-stage precision oncology company develops targeted small-molecule therapeutics, including CDK and FGFR inhibitors, for patients with diverse cancer types.

Nuvalent

This biopharmaceutical company develops targeted small molecule kinase inhibitors for patients with genomically defined cancers such as non-small cell lung cancer.